Philips to distribute Corindus robotic-assisted PCI system

| | Health Exec | Artificial Intelligence
Robotics - 164.83 Kb
Corindus Vascular Robotics receives FDA 510(k) clearance for the CorPath 200 System to assist interventional cardiologists in performing PCI. Source: Corindus Vascular Robotics
Royal Philips Electronics and Corindus Vascular Robotics have signed a U.S. distribution agreement for Corindus’ CorPath 200 system, the recently FDA-approved robotic-assisted system to be used during PCI procedures.

The financial details of the exclusive distribution agreement were not disclosed. Philips owns a minority share in the Natick, Mass.-based Corindus, which commercializes robotic-assisted systems for interventional cardiology procedures.

The CorPath 200 system can be integrated with x-ray fluoroscopy systems including Philips’ Allura x-ray equipment. The robotic-assisted system can be used with standard stents, catheters and guidewires, the companies said in a press release. The CorPath 200 system is operated by the interventional cardiologist from a radiation shielded, interventional cockpit.

The distribution agreement enables both companies to sell the robotic-assisted system in the U.S.

Related Content

Generative AI isn’t changing everything for patients and providers—but it’s not leaving much unaffected, either
Antibiotics prescriptions: There’s a large-language model for that
LAAO or DOAC? Mayo Clinic AI helps guide treatment of AFib patients
4 important AMA insights into physician thinking on, behavior with healthcare AI
Global consortium: The future of AI in healthcare is dynamic—and demanding
Gottlieb: Let’s not slap the label ‘medical device’ on AI software that only helps clinicians make care decisions

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”